Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
- Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.
Supernus Pharmaceuticals Stock Performance
Shares of SUPN stock traded up $0.48 on Thursday, reaching $52.09. The stock had a trading volume of 92,294 shares, compared to its average volume of 718,922. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $59.68. The stock has a market cap of $3.00 billion, a P/E ratio of -76.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.73. The company has a 50 day simple moving average of $51.24 and a 200 day simple moving average of $49.67.
Institutional Trading of Supernus Pharmaceuticals
Insiders Place Their Bets
In other news, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 50,000 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $50.28, for a total value of $2,514,000.00. Following the sale, the vice president owned 17,044 shares of the company’s stock, valued at $856,972.32. This represents a 74.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 120,881 shares of company stock valued at $6,139,356. Insiders own 8.80% of the company’s stock.
Wall Street Analyst Weigh In
SUPN has been the topic of several research reports. Stifel Nicolaus raised their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $62.17.
Read Our Latest Stock Analysis on Supernus Pharmaceuticals
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
See Also
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
